[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f6su717JjdlDHPlI8pmhDLJ6AM3IvbtC2Jp9bq_Bq-C0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":53,"rows":60},"Khon Kaen University",[4],159,false,8,20,25241,5,105,[14,16,18,21,24,26,28,30],{"name":15,"count":11},"Healthy",{"name":17,"count":11},"Spinal Cord Injuries",{"name":19,"count":20},"Postoperative Nausea and Vomiting",4,{"name":22,"count":23},"Systemic Sclerosis",3,{"name":25,"count":23},"Anesthesia",{"name":27,"count":23},"Injuries, Spinal Cord",{"name":29,"count":23},"Postoperative Pain",{"name":31,"count":23},"Postoperative Complications",[33,38,43,48],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06622213","Mucoadhesive Film With\u002Fwithout Acmella Oleracea & Triamcinolone Acetonide for Aphthous Ulcers","2025-05","Triamcinolone Acetonide 0.1% Oromucosal Paste",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT07054775","Comparison of Pruritus Incidence After Intrathecal Morphine 0.1 vs 0.2 mg in Cesarean Section","2025-10-31","Morphine Sulfate",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06994520","Efficacy of Topical Cannabidiol for Eczema","2026-05-01","Triamcinolone (TAC) 0.1% cream",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT07245238","Topical Cannabidiol Lotion for Pruritus Relief in Scleroderma","2027-12","10% urea lotion plus 1% cannabidiol",[54,55,56,57,58,59],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[61,86,111,129,156,179,210,228,255,273,299,324,350,374,401,419,437,463,489,536,569,596,614,639,669,687,705,723,748,775,798,824,842,868,893,911,936,954,980,1004,1022,1046,1073,1099,1117,1141,1167,1185,1209,1235,1253,1280,1321,1355,1392,1415,1433,1457,1482,1500,1523,1545,1570,1588,1613,1631,1657,1681,1699,1717,1735,1758],{"intervention":42,"totalTrials":62,"cells":63},1,{"EARLY_PHASE1":64,"PHASE1":67,"PHASE2":69,"PHASE3":71,"PHASE4":73,"NA":84},{"trials":65,"activeCount":66},[],0,{"trials":68,"activeCount":66},[],{"trials":70,"activeCount":66},[],{"trials":72,"activeCount":66},[],{"trials":74,"activeCount":62,"soonestReadout":41},[75],{"nctId":39,"briefTitle":40,"status":76,"phases":77,"primaryCompletion":41,"completion":78,"start":79,"enrollment":80,"conditions":81,"interventions":83},"RECRUITING",[58],"2025-11-30","2025-06-01",69,[82],"Pruritus Caused by Drug",[42],{"trials":85,"activeCount":66},[],{"intervention":52,"totalTrials":62,"cells":87},{"EARLY_PHASE1":88,"PHASE1":90,"PHASE2":92,"PHASE3":94,"PHASE4":107,"NA":109},{"trials":89,"activeCount":66},[],{"trials":91,"activeCount":66},[],{"trials":93,"activeCount":66},[],{"trials":95,"activeCount":62,"soonestReadout":51},[96],{"nctId":49,"briefTitle":50,"status":76,"phases":97,"primaryCompletion":51,"completion":98,"start":99,"enrollment":100,"conditions":101,"interventions":105},[57],"2028-12","2025-11-05",36,[102,103,104],"Mediciine","Systemic Sclerosis (SSc)","Intervention Study",[52,106],"Control",{"trials":108,"activeCount":66},[],{"trials":110,"activeCount":66},[],{"intervention":106,"totalTrials":62,"cells":112},{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":117,"PHASE3":119,"PHASE4":125,"NA":127},{"trials":114,"activeCount":66},[],{"trials":116,"activeCount":66},[],{"trials":118,"activeCount":66},[],{"trials":120,"activeCount":62,"soonestReadout":51},[121],{"nctId":49,"briefTitle":50,"status":76,"phases":122,"primaryCompletion":51,"completion":98,"start":99,"enrollment":100,"conditions":123,"interventions":124},[57],[102,103,104],[52,106],{"trials":126,"activeCount":66},[],{"trials":128,"activeCount":66},[],{"intervention":47,"totalTrials":62,"cells":130},{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":150,"PHASE4":152,"NA":154},{"trials":132,"activeCount":66},[],{"trials":134,"activeCount":66},[],{"trials":136,"activeCount":62,"soonestReadout":46},[137],{"nctId":44,"briefTitle":45,"status":138,"phases":139,"primaryCompletion":46,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":149},"ACTIVE_NOT_RECRUITING",[56],"2026-12-31","2025-05-01",60,[144,145,146,147,148],"Chronic Pruritus","Eczema","Nummular Eczema","Atopic Dermatitis","Prurigo Nodularis",[47],{"trials":151,"activeCount":66},[],{"trials":153,"activeCount":66},[],{"trials":155,"activeCount":66},[],{"intervention":37,"totalTrials":62,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":173,"PHASE4":175,"NA":177},{"trials":159,"activeCount":66},[],{"trials":161,"activeCount":66},[],{"trials":163,"activeCount":62,"soonestReadout":36},[164],{"nctId":34,"briefTitle":35,"status":165,"phases":166,"primaryCompletion":36,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":172},"NOT_YET_RECRUITING",[56],"2026-05","2024-10-15",72,[171],"Aphthous Stomatitis",[37],{"trials":174,"activeCount":66},[],{"trials":176,"activeCount":66},[],{"trials":178,"activeCount":66},[],{"intervention":180,"totalTrials":62,"cells":181},"lidocaine spray",{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":190,"NA":208},{"trials":183,"activeCount":66},[],{"trials":185,"activeCount":66},[],{"trials":187,"activeCount":66},[],{"trials":189,"activeCount":66},[],{"trials":191,"activeCount":66},[192],{"nctId":193,"briefTitle":194,"status":195,"phases":196,"primaryCompletion":197,"completion":36,"start":198,"enrollment":199,"conditions":200,"interventions":206},"NCT06226532","Effect of Lidocaine Sprayed for Attenuating Hemodynamic Response During Laryngoscopy and Intubation","UNKNOWN",[58],"2025-01","2024-01",50,[201,202,203,204,205],"Laryngoscopy","Intubation","Hemodynamics","Neurosurgery","Lidocaine",[180,207],"Intravenous Lidocaine",{"trials":209,"activeCount":66},[],{"intervention":207,"totalTrials":62,"cells":211},{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":218,"PHASE4":220,"NA":226},{"trials":213,"activeCount":66},[],{"trials":215,"activeCount":66},[],{"trials":217,"activeCount":66},[],{"trials":219,"activeCount":66},[],{"trials":221,"activeCount":66},[222],{"nctId":193,"briefTitle":194,"status":195,"phases":223,"primaryCompletion":197,"completion":36,"start":198,"enrollment":199,"conditions":224,"interventions":225},[58],[201,202,203,204,205],[180,207],{"trials":227,"activeCount":66},[],{"intervention":229,"totalTrials":62,"cells":230},"Co-trimoxazole 12",{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":239,"NA":253},{"trials":232,"activeCount":66},[],{"trials":234,"activeCount":66},[],{"trials":236,"activeCount":66},[],{"trials":238,"activeCount":66},[],{"trials":240,"activeCount":66},[241],{"nctId":242,"briefTitle":243,"status":244,"phases":245,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":251},"NCT01420341","Co-trimoxazole as Maintenance Therapy for Melioidosis","COMPLETED",[58],"2019-06-21","2011-08",667,[250],"Melioidosis",[229,252],"Co-trimoxazole 20",{"trials":254,"activeCount":66},[],{"intervention":252,"totalTrials":62,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":265,"NA":271},{"trials":258,"activeCount":66},[],{"trials":260,"activeCount":66},[],{"trials":262,"activeCount":66},[],{"trials":264,"activeCount":66},[],{"trials":266,"activeCount":66},[267],{"nctId":242,"briefTitle":243,"status":244,"phases":268,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":269,"interventions":270},[58],[250],[229,252],{"trials":272,"activeCount":66},[],{"intervention":274,"totalTrials":62,"cells":275},"1% tropicamide and 2.5% phenylephrine",{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":297},{"trials":277,"activeCount":66},[],{"trials":279,"activeCount":66},[],{"trials":281,"activeCount":66},[],{"trials":283,"activeCount":66},[],{"trials":285,"activeCount":66},[286],{"nctId":287,"briefTitle":288,"status":244,"phases":289,"primaryCompletion":290,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":296},"NCT00877175","Comparison of Instillation and Packing in Mydriasis for Premature Infants",[58],"2009-05","2009-06","2009-03",25,[295],"Preterm Infants",[274],{"trials":298,"activeCount":66},[],{"intervention":300,"totalTrials":62,"cells":301},"2.5% or 10% phenylephrine",{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":310,"NA":322},{"trials":303,"activeCount":66},[],{"trials":305,"activeCount":66},[],{"trials":307,"activeCount":66},[],{"trials":309,"activeCount":66},[],{"trials":311,"activeCount":66},[312],{"nctId":313,"briefTitle":314,"status":244,"phases":315,"completion":316,"start":317,"enrollment":318,"conditions":319,"interventions":321},"NCT00501878","2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides",[58],"2007-07","2007-05",100,[320],"Diabetes Mellitus",[300],{"trials":323,"activeCount":66},[],{"intervention":325,"totalTrials":62,"cells":326},"Japanese encephalitis chimeric vaccine",{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":335,"NA":348},{"trials":328,"activeCount":66},[],{"trials":330,"activeCount":66},[],{"trials":332,"activeCount":66},[],{"trials":334,"activeCount":66},[],{"trials":336,"activeCount":66},[337],{"nctId":338,"briefTitle":339,"status":195,"phases":340,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":347},"NCT01954810","Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children",[58],"2013-12","2014-05","2013-10",88,[346],"Japanese Encephalitis",[325],{"trials":349,"activeCount":66},[],{"intervention":351,"totalTrials":62,"cells":352},"Gabapentin",{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":359,"PHASE4":361,"NA":372},{"trials":354,"activeCount":66},[],{"trials":356,"activeCount":66},[],{"trials":358,"activeCount":66},[],{"trials":360,"activeCount":66},[],{"trials":362,"activeCount":66},[363],{"nctId":364,"briefTitle":365,"status":244,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":371},"NCT02944981","Gabapentin to Reduce Postoperative Nausea and Vomiting",[58],"2017-02","2016-08",80,[19],[351],{"trials":373,"activeCount":66},[],{"intervention":375,"totalTrials":62,"cells":376},"Dexmedetomidine",{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":399},{"trials":378,"activeCount":66},[],{"trials":380,"activeCount":66},[],{"trials":382,"activeCount":66},[],{"trials":384,"activeCount":66},[],{"trials":386,"activeCount":66},[387],{"nctId":388,"briefTitle":389,"status":244,"phases":390,"primaryCompletion":391,"completion":391,"start":392,"enrollment":142,"conditions":393,"interventions":396},"NCT03077503","Comparison of Dexmedetomidine and Fentanyl to Prevent Hemodynamic Response to Skull Pins Application",[58],"2016-09-30","2015-09-01",[394,395],"Hemodynamic Response","Skull Pins Application",[375,397,398],"Fentanyl","0.9% normal saline",{"trials":400,"activeCount":66},[],{"intervention":397,"totalTrials":62,"cells":402},{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":409,"PHASE4":411,"NA":417},{"trials":404,"activeCount":66},[],{"trials":406,"activeCount":66},[],{"trials":408,"activeCount":66},[],{"trials":410,"activeCount":66},[],{"trials":412,"activeCount":66},[413],{"nctId":388,"briefTitle":389,"status":244,"phases":414,"primaryCompletion":391,"completion":391,"start":392,"enrollment":142,"conditions":415,"interventions":416},[58],[394,395],[375,397,398],{"trials":418,"activeCount":66},[],{"intervention":398,"totalTrials":62,"cells":420},{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":429,"NA":435},{"trials":422,"activeCount":66},[],{"trials":424,"activeCount":66},[],{"trials":426,"activeCount":66},[],{"trials":428,"activeCount":66},[],{"trials":430,"activeCount":66},[431],{"nctId":388,"briefTitle":389,"status":244,"phases":432,"primaryCompletion":391,"completion":391,"start":392,"enrollment":142,"conditions":433,"interventions":434},[58],[394,395],[375,397,398],{"trials":436,"activeCount":66},[],{"intervention":438,"totalTrials":62,"cells":439},"intravitreal injection of bevacizumab",{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":448,"NA":461},{"trials":441,"activeCount":66},[],{"trials":443,"activeCount":66},[],{"trials":445,"activeCount":66},[],{"trials":447,"activeCount":66},[],{"trials":449,"activeCount":66},[450],{"nctId":451,"briefTitle":452,"status":244,"phases":453,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":460},"NCT01724385","Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy",[58],"2012-12","2012-08",18,[458,459],"Vitreous Hemorrhage","Proliferative Diabetic Retinopathy",[438],{"trials":462,"activeCount":66},[],{"intervention":464,"totalTrials":62,"cells":465},"Loteprednol etabonate",{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":474,"NA":487},{"trials":467,"activeCount":66},[],{"trials":469,"activeCount":66},[],{"trials":471,"activeCount":66},[],{"trials":473,"activeCount":66},[],{"trials":475,"activeCount":66},[476],{"nctId":477,"briefTitle":478,"status":244,"phases":479,"primaryCompletion":480,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":485},"NCT01724892","Comparison the Effects of Dexamethasone and Loteprednol on Epithelial Healing",[58],"2013-09","2012-11",32,[484],"Epithelial Defect After Phototherapeutic Keratectomy",[486,464],"Dexamethasone",{"trials":488,"activeCount":66},[],{"intervention":490,"totalTrials":23,"cells":491},"Melatonin",{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":519,"PHASE4":532,"NA":534},{"trials":493,"activeCount":66},[],{"trials":495,"activeCount":66},[],{"trials":497,"activeCount":66},[498,509],{"nctId":499,"briefTitle":500,"status":244,"phases":501,"primaryCompletion":502,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":507},"NCT02430298","Topical\u002FOral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis\u002FXerostomia Cancer Patients",[56],"2015-12","2013-07",39,[506],"Head and Neck Cancer",[490,508],"Matched Placebo",{"nctId":510,"briefTitle":511,"status":195,"phases":512,"primaryCompletion":368,"completion":513,"start":514,"enrollment":515,"conditions":516,"interventions":518},"NCT02845778","Pharmacokinetics of Melatonin Niosomes Oral Gel in Healthy Volunteers",[55,56],"2017-03","2016-05",15,[517],"Pharmacokinetics of Melatonin",[490],{"trials":520,"activeCount":66},[521],{"nctId":522,"briefTitle":523,"status":195,"phases":524,"primaryCompletion":525,"start":526,"enrollment":527,"conditions":528,"interventions":530},"NCT01557478","Melatonin as Adjuvant Therapy in Breast Cancer Patients",[56,57],"2016-09","2012-03",166,[529],"Stage II and III Breast Cancer",[490,531],"match placebo",{"trials":533,"activeCount":66},[],{"trials":535,"activeCount":66},[],{"intervention":537,"totalTrials":538,"cells":539},"Matched placebo",2,{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":550,"PHASE4":565,"NA":567},{"trials":541,"activeCount":66},[],{"trials":543,"activeCount":66},[],{"trials":545,"activeCount":66},[546],{"nctId":499,"briefTitle":500,"status":244,"phases":547,"primaryCompletion":502,"completion":502,"start":503,"enrollment":504,"conditions":548,"interventions":549},[56],[506],[490,508],{"trials":551,"activeCount":66},[552],{"nctId":553,"briefTitle":554,"status":244,"phases":555,"primaryCompletion":556,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":562},"NCT01706627","Melatonin In Reduction of Chemotherapy-Induced Toxicity (MIRCIT) Trial",[56,57],"2011-12","2012-06","2007-08",175,[561],"Advanced Stage Cancer",[563,564,537],"10 mg Melatonin","20 mg Melatonin",{"trials":566,"activeCount":66},[],{"trials":568,"activeCount":66},[],{"intervention":570,"totalTrials":62,"cells":571},"Alginic acid",{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":592,"NA":594},{"trials":573,"activeCount":66},[],{"trials":575,"activeCount":66},[],{"trials":577,"activeCount":66},[],{"trials":579,"activeCount":66},[580],{"nctId":581,"briefTitle":582,"status":244,"phases":583,"primaryCompletion":584,"completion":585,"start":586,"enrollment":369,"conditions":587,"interventions":590},"NCT01878526","Gastroesophageal Reflux Treatment in Scleroderma",[57],"2015-08","2016-01","2013-06",[588,22,589],"Gastroesophageal Reflux Disease","Scleroderma",[570,591],"Domperidone",{"trials":593,"activeCount":66},[],{"trials":595,"activeCount":66},[],{"intervention":591,"totalTrials":62,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":610,"NA":612},{"trials":599,"activeCount":66},[],{"trials":601,"activeCount":66},[],{"trials":603,"activeCount":66},[],{"trials":605,"activeCount":66},[606],{"nctId":581,"briefTitle":582,"status":244,"phases":607,"primaryCompletion":584,"completion":585,"start":586,"enrollment":369,"conditions":608,"interventions":609},[57],[588,22,589],[570,591],{"trials":611,"activeCount":66},[],{"trials":613,"activeCount":66},[],{"intervention":615,"totalTrials":62,"cells":616},"tranexamic acid",{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":635,"NA":637},{"trials":618,"activeCount":66},[],{"trials":620,"activeCount":66},[],{"trials":622,"activeCount":66},[],{"trials":624,"activeCount":66},[625],{"nctId":626,"briefTitle":627,"status":244,"phases":628,"primaryCompletion":629,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":634},"NCT00755209","Tranexamic Acid for Preventing Progressive Intracranial Haemorrhage in Traumatic Brain Injury",[57],"2009-10","2008-10",238,[633],"Brain Injuries",[615],{"trials":636,"activeCount":66},[],{"trials":638,"activeCount":66},[],{"intervention":640,"totalTrials":62,"cells":641},"Sitafloxacin",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":665,"NA":667},{"trials":643,"activeCount":66},[],{"trials":645,"activeCount":66},[],{"trials":647,"activeCount":66},[],{"trials":649,"activeCount":66},[650],{"nctId":651,"briefTitle":652,"status":195,"phases":653,"primaryCompletion":654,"completion":198,"start":655,"enrollment":656,"conditions":657,"interventions":663},"NCT02729116","Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients",[56,57],"2023-12","2016-07",30,[658,659,660,661,662],"Anti-Infective Agents, Urinary","Escherichia Coli Infections","Klebsiella Infections","Kidney Transplantation","Urinary Tract Infections",[640,664],"Ertapenem",{"trials":666,"activeCount":66},[],{"trials":668,"activeCount":66},[],{"intervention":664,"totalTrials":62,"cells":670},{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":683,"NA":685},{"trials":672,"activeCount":66},[],{"trials":674,"activeCount":66},[],{"trials":676,"activeCount":66},[],{"trials":678,"activeCount":66},[679],{"nctId":651,"briefTitle":652,"status":195,"phases":680,"primaryCompletion":654,"completion":198,"start":655,"enrollment":656,"conditions":681,"interventions":682},[56,57],[658,659,660,661,662],[640,664],{"trials":684,"activeCount":66},[],{"trials":686,"activeCount":66},[],{"intervention":563,"totalTrials":62,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":701,"NA":703},{"trials":690,"activeCount":66},[],{"trials":692,"activeCount":66},[],{"trials":694,"activeCount":66},[],{"trials":696,"activeCount":66},[697],{"nctId":553,"briefTitle":554,"status":244,"phases":698,"primaryCompletion":556,"completion":557,"start":558,"enrollment":559,"conditions":699,"interventions":700},[56,57],[561],[563,564,537],{"trials":702,"activeCount":66},[],{"trials":704,"activeCount":66},[],{"intervention":564,"totalTrials":62,"cells":706},{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":719,"NA":721},{"trials":708,"activeCount":66},[],{"trials":710,"activeCount":66},[],{"trials":712,"activeCount":66},[],{"trials":714,"activeCount":66},[715],{"nctId":553,"briefTitle":554,"status":244,"phases":716,"primaryCompletion":556,"completion":557,"start":558,"enrollment":559,"conditions":717,"interventions":718},[56,57],[561],[563,564,537],{"trials":720,"activeCount":66},[],{"trials":722,"activeCount":66},[],{"intervention":724,"totalTrials":62,"cells":725},"Plavina cream",{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":732,"PHASE4":744,"NA":746},{"trials":727,"activeCount":66},[],{"trials":729,"activeCount":66},[],{"trials":731,"activeCount":66},[],{"trials":733,"activeCount":66},[734],{"nctId":735,"briefTitle":736,"status":244,"phases":737,"primaryCompletion":586,"completion":738,"start":739,"enrollment":740,"conditions":741,"interventions":743},"NCT01836393","Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 14% of Plai (Plaivana®) to Placebo Gels",[57],"2014-04","2013-01",120,[742],"Knee Osteoarthritis",[724],{"trials":745,"activeCount":66},[],{"trials":747,"activeCount":66},[],{"intervention":749,"totalTrials":62,"cells":750},"a single-dose of Etoricoxib before induction of anesthesia",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":771,"NA":773},{"trials":752,"activeCount":66},[],{"trials":754,"activeCount":66},[],{"trials":756,"activeCount":66},[],{"trials":758,"activeCount":66},[759],{"nctId":760,"briefTitle":761,"status":244,"phases":762,"completion":763,"start":764,"enrollment":199,"conditions":765,"interventions":770},"NCT00149253","Pre-Emptive Analgesia Efficacy of Etoricoxib for Postoperative Pain",[57],"2005-05","2004-12",[766,767,768,769],"a Single-Dose of Etoricoxib","Post-Operative Morphine Consumption","Total Pain Relief Over 8 Hr(TOPAR8)","Post Transabdominal Hysterectomy",[749],{"trials":772,"activeCount":66},[],{"trials":774,"activeCount":66},[],{"intervention":776,"totalTrials":62,"cells":777},"1% tropicamide and 10% phenylephrine",{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":794,"NA":796},{"trials":779,"activeCount":66},[],{"trials":781,"activeCount":66},[],{"trials":783,"activeCount":66},[],{"trials":785,"activeCount":66},[786],{"nctId":787,"briefTitle":788,"status":244,"phases":789,"completion":790,"start":764,"enrollment":369,"conditions":791,"interventions":793},"NCT00120432","Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation",[57],"2005-06",[792],"Eye Diseases",[776],{"trials":795,"activeCount":66},[],{"trials":797,"activeCount":66},[],{"intervention":799,"totalTrials":62,"cells":800},"Intralesional injection of bevacizumab",{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":820,"NA":822},{"trials":802,"activeCount":66},[],{"trials":804,"activeCount":66},[],{"trials":806,"activeCount":66},[],{"trials":808,"activeCount":66},[809],{"nctId":810,"briefTitle":811,"status":195,"phases":812,"primaryCompletion":454,"completion":454,"start":813,"enrollment":814,"conditions":815,"interventions":818},"NCT01380678","Intralesional Bevacizumab Injection on Primary Pterygium",[57],"2009-01",206,[816,817],"Pterygium","Inflammation",[799,819],"Topical antihistamine and vasoconstrictor",{"trials":821,"activeCount":66},[],{"trials":823,"activeCount":66},[],{"intervention":819,"totalTrials":62,"cells":825},{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":832,"PHASE4":838,"NA":840},{"trials":827,"activeCount":66},[],{"trials":829,"activeCount":66},[],{"trials":831,"activeCount":66},[],{"trials":833,"activeCount":66},[834],{"nctId":810,"briefTitle":811,"status":195,"phases":835,"primaryCompletion":454,"completion":454,"start":813,"enrollment":814,"conditions":836,"interventions":837},[57],[816,817],[799,819],{"trials":839,"activeCount":66},[],{"trials":841,"activeCount":66},[],{"intervention":843,"totalTrials":62,"cells":844},"0.0125% Capsaicin gel \"CAPSIKA gel\"",{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":849,"PHASE3":851,"PHASE4":864,"NA":866},{"trials":846,"activeCount":66},[],{"trials":848,"activeCount":66},[],{"trials":850,"activeCount":66},[],{"trials":852,"activeCount":66},[853],{"nctId":854,"briefTitle":855,"status":244,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":318,"conditions":860,"interventions":863},"NCT00471055","Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 0.0125% of Capsaicin to Placebo",[57],"2007-10","2007-12","2007-06",[861,862],"Osteoarthritis, Knee Joint","Capsicum",[843],{"trials":865,"activeCount":66},[],{"trials":867,"activeCount":66},[],{"intervention":869,"totalTrials":62,"cells":870},"Cleanoze®",{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":889,"NA":891},{"trials":872,"activeCount":66},[],{"trials":874,"activeCount":66},[],{"trials":876,"activeCount":66},[],{"trials":878,"activeCount":66},[879],{"nctId":880,"briefTitle":881,"status":244,"phases":882,"primaryCompletion":883,"completion":883,"start":585,"enrollment":884,"conditions":885,"interventions":887},"NCT02763241","Cleanoze® Irrigation Device With Powder Preparation Versus Conventional Irrigation Method for Chronic Rhinitis",[57],"2018-01",115,[886],"Rhinitis",[869,888],"Saline",{"trials":890,"activeCount":66},[],{"trials":892,"activeCount":66},[],{"intervention":888,"totalTrials":62,"cells":894},{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":901,"PHASE4":907,"NA":909},{"trials":896,"activeCount":66},[],{"trials":898,"activeCount":66},[],{"trials":900,"activeCount":66},[],{"trials":902,"activeCount":66},[903],{"nctId":880,"briefTitle":881,"status":244,"phases":904,"primaryCompletion":883,"completion":883,"start":585,"enrollment":884,"conditions":905,"interventions":906},[57],[886],[869,888],{"trials":908,"activeCount":66},[],{"trials":910,"activeCount":66},[],{"intervention":912,"totalTrials":62,"cells":913},"25 mg sodium hyaluronate \"GO ON\"",{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":920,"PHASE4":932,"NA":934},{"trials":915,"activeCount":66},[],{"trials":917,"activeCount":66},[],{"trials":919,"activeCount":66},[],{"trials":921,"activeCount":66},[922],{"nctId":923,"briefTitle":924,"status":244,"phases":925,"primaryCompletion":926,"completion":629,"start":927,"enrollment":142,"conditions":928,"interventions":930},"NCT00750724","Efficacy Study of \"Go On\" in Magnetic Resonance Imaging (MRI) Improvement in Osteoarthritis (OA) Knee",[57],"2009-09","2008-07",[929],"Osteoarthritis",[912,931],"normal saline,2 ml., intraarticular weekly for 5 weeks",{"trials":933,"activeCount":66},[],{"trials":935,"activeCount":66},[],{"intervention":931,"totalTrials":62,"cells":937},{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":944,"PHASE4":950,"NA":952},{"trials":939,"activeCount":66},[],{"trials":941,"activeCount":66},[],{"trials":943,"activeCount":66},[],{"trials":945,"activeCount":66},[946],{"nctId":923,"briefTitle":924,"status":244,"phases":947,"primaryCompletion":926,"completion":629,"start":927,"enrollment":142,"conditions":948,"interventions":949},[57],[929],[912,931],{"trials":951,"activeCount":66},[],{"trials":953,"activeCount":66},[],{"intervention":955,"totalTrials":62,"cells":956},"CBD oil",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":963,"PHASE4":976,"NA":978},{"trials":958,"activeCount":66},[],{"trials":960,"activeCount":66},[],{"trials":962,"activeCount":66},[],{"trials":964,"activeCount":66},[965],{"nctId":966,"briefTitle":967,"status":244,"phases":968,"primaryCompletion":969,"completion":970,"start":971,"enrollment":656,"conditions":972,"interventions":975},"NCT05416697","Effectiveness of Cannabinoids on Appetite in Scleroderma",[57],"2024-10-31","2024-12-31","2022-11-09",[22,973,974],"Malnutrition","Loss of Appetite",[955],{"trials":977,"activeCount":66},[],{"trials":979,"activeCount":66},[],{"intervention":981,"totalTrials":62,"cells":982},"Anthocyanin",{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":989,"PHASE4":1000,"NA":1002},{"trials":984,"activeCount":66},[],{"trials":986,"activeCount":66},[],{"trials":988,"activeCount":66},[],{"trials":990,"activeCount":66},[991],{"nctId":992,"briefTitle":993,"status":244,"phases":994,"primaryCompletion":585,"completion":585,"start":584,"enrollment":995,"conditions":996,"interventions":999},"NCT02536781","Efficacy of Anthocyanin Mouthrinse for Oral Anti-inflammation From Orthodontic Treatment",[56,57],70,[997,998],"Inflammation of Mouth","Acute Mucous Inflammation",[981],{"trials":1001,"activeCount":66},[],{"trials":1003,"activeCount":66},[],{"intervention":531,"totalTrials":62,"cells":1005},{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1012,"PHASE4":1018,"NA":1020},{"trials":1007,"activeCount":66},[],{"trials":1009,"activeCount":66},[],{"trials":1011,"activeCount":66},[],{"trials":1013,"activeCount":66},[1014],{"nctId":522,"briefTitle":523,"status":195,"phases":1015,"primaryCompletion":525,"start":526,"enrollment":527,"conditions":1016,"interventions":1017},[56,57],[529],[490,531],{"trials":1019,"activeCount":66},[],{"trials":1021,"activeCount":66},[],{"intervention":1023,"totalTrials":62,"cells":1024},"Prednisolone and taper",{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1040,"PHASE4":1042,"NA":1044},{"trials":1026,"activeCount":66},[],{"trials":1028,"activeCount":66},[],{"trials":1030,"activeCount":66},[1031],{"nctId":1032,"briefTitle":1033,"status":244,"phases":1034,"primaryCompletion":1035,"completion":1035,"start":1036,"enrollment":9,"conditions":1037,"interventions":1039},"NCT03607071","Outcome of Steroid Therapy for Myocardial Inflammation in Scleroderma",[56],"2019-06-30","2018-05-15",[1038],"Myocardial Inflammation",[1023],{"trials":1041,"activeCount":66},[],{"trials":1043,"activeCount":66},[],{"trials":1045,"activeCount":66},[],{"intervention":1047,"totalTrials":62,"cells":1048},"Olanzapine",{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1067,"PHASE4":1069,"NA":1071},{"trials":1050,"activeCount":66},[],{"trials":1052,"activeCount":66},[],{"trials":1054,"activeCount":66},[1055],{"nctId":1056,"briefTitle":1057,"status":195,"phases":1058,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":515,"conditions":1062,"interventions":1066},"NCT03679182","Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care",[56],"2020-09","2021-09","2018-09-01",[1063,1064,1065],"Nausea","Vomiting","End Stage Cancer",[1047],{"trials":1068,"activeCount":66},[],{"trials":1070,"activeCount":66},[],{"trials":1072,"activeCount":66},[],{"intervention":1074,"totalTrials":62,"cells":1075},"Budesonide nasal instillation",{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1093,"PHASE4":1095,"NA":1097},{"trials":1077,"activeCount":66},[],{"trials":1079,"activeCount":66},[],{"trials":1081,"activeCount":66},[1082],{"nctId":1083,"briefTitle":1084,"status":195,"phases":1085,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":142,"conditions":1088,"interventions":1091},"NCT02862509","Effectiveness of Budesonide Nasal Instillation in a Vertex-to-floor Position",[56],"2017-08","2015-11",[1089,1090],"Chronic Frontal Rhinosinusitis","Vertex to Floor Position",[1074,1092],"Normal saline nasal instillation",{"trials":1094,"activeCount":66},[],{"trials":1096,"activeCount":66},[],{"trials":1098,"activeCount":66},[],{"intervention":1092,"totalTrials":62,"cells":1100},{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1102,"activeCount":66},[],{"trials":1104,"activeCount":66},[],{"trials":1106,"activeCount":66},[1107],{"nctId":1083,"briefTitle":1084,"status":195,"phases":1108,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":142,"conditions":1109,"interventions":1110},[56],[1089,1090],[1074,1092],{"trials":1112,"activeCount":66},[],{"trials":1114,"activeCount":66},[],{"trials":1116,"activeCount":66},[],{"intervention":1118,"totalTrials":62,"cells":1119},"mFOLFOXIRI",{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1135,"PHASE4":1137,"NA":1139},{"trials":1121,"activeCount":66},[],{"trials":1123,"activeCount":66},[],{"trials":1125,"activeCount":66},[1126],{"nctId":1127,"briefTitle":1128,"status":195,"phases":1129,"primaryCompletion":1130,"completion":654,"start":1131,"enrollment":293,"conditions":1132,"interventions":1134},"NCT03603834","Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma",[56],"2023-08","2018-09-19",[1133],"Cholangiocarcinoma",[1118],{"trials":1136,"activeCount":66},[],{"trials":1138,"activeCount":66},[],{"trials":1140,"activeCount":66},[],{"intervention":1142,"totalTrials":62,"cells":1143},"preseptal injection of botulinum toxin type A",{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1161,"PHASE4":1163,"NA":1165},{"trials":1145,"activeCount":66},[],{"trials":1147,"activeCount":66},[],{"trials":1149,"activeCount":66},[1150],{"nctId":1151,"briefTitle":1152,"status":195,"phases":1153,"primaryCompletion":1154,"completion":454,"start":1155,"enrollment":1156,"conditions":1157,"interventions":1159},"NCT01564979","Effect on Tear Functions of Pretarsal and Preseptal Techniques of Botulinum Toxin Type A Injection in Hemifacial Spasm",[56],"2012-09","2012-04",26,[1158],"Hemifacial Spasm",[1142,1160],"pretarsal injection of Botulinum toxin type A",{"trials":1162,"activeCount":66},[],{"trials":1164,"activeCount":66},[],{"trials":1166,"activeCount":66},[],{"intervention":1160,"totalTrials":62,"cells":1168},{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1179,"PHASE4":1181,"NA":1183},{"trials":1170,"activeCount":66},[],{"trials":1172,"activeCount":66},[],{"trials":1174,"activeCount":66},[1175],{"nctId":1151,"briefTitle":1152,"status":195,"phases":1176,"primaryCompletion":1154,"completion":454,"start":1155,"enrollment":1156,"conditions":1177,"interventions":1178},[56],[1158],[1142,1160],{"trials":1180,"activeCount":66},[],{"trials":1182,"activeCount":66},[],{"trials":1184,"activeCount":66},[],{"intervention":1186,"totalTrials":62,"cells":1187},"Cannabis",{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1201,"PHASE3":1203,"PHASE4":1205,"NA":1207},{"trials":1189,"activeCount":66},[],{"trials":1191,"activeCount":66},[1192],{"nctId":1193,"briefTitle":1194,"status":195,"phases":1195,"primaryCompletion":1196,"completion":1196,"start":1197,"enrollment":9,"conditions":1198,"interventions":1200},"NCT06190470","Effects of Marijuana on Neuropathic Pain and Spasticity in Spinal Cord Injury Patients",[55],"2024-06-30","2024-01-02",[1199],"Spinal Cord Injury",[1186],{"trials":1202,"activeCount":66},[],{"trials":1204,"activeCount":66},[],{"trials":1206,"activeCount":66},[],{"trials":1208,"activeCount":66},[],{"intervention":1210,"totalTrials":62,"cells":1211},"Generic clopidogrel product Apolets®",{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1227,"PHASE3":1229,"PHASE4":1231,"NA":1233},{"trials":1213,"activeCount":66},[],{"trials":1215,"activeCount":66},[1216],{"nctId":1217,"briefTitle":1218,"status":244,"phases":1219,"primaryCompletion":1220,"completion":1221,"start":1222,"enrollment":482,"conditions":1223,"interventions":1225},"NCT02010632","Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products",[55],"2014-10","2014-12","2013-08",[1224],"Pharmacodynamics",[1210,1226],"Original clopidogrel product Plavix®",{"trials":1228,"activeCount":66},[],{"trials":1230,"activeCount":66},[],{"trials":1232,"activeCount":66},[],{"trials":1234,"activeCount":66},[],{"intervention":1226,"totalTrials":62,"cells":1236},{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1245,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1238,"activeCount":66},[],{"trials":1240,"activeCount":66},[1241],{"nctId":1217,"briefTitle":1218,"status":244,"phases":1242,"primaryCompletion":1220,"completion":1221,"start":1222,"enrollment":482,"conditions":1243,"interventions":1244},[55],[1224],[1210,1226],{"trials":1246,"activeCount":66},[],{"trials":1248,"activeCount":66},[],{"trials":1250,"activeCount":66},[],{"trials":1252,"activeCount":66},[],{"intervention":1254,"totalTrials":62,"cells":1255},"Omeprazole 20mg",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1272,"PHASE3":1274,"PHASE4":1276,"NA":1278},{"trials":1257,"activeCount":66},[],{"trials":1259,"activeCount":66},[1260],{"nctId":1261,"briefTitle":1262,"status":244,"phases":1263,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":1267,"conditions":1268,"interventions":1271},"NCT03561233","Prevalence and Predictors of Proton Pump Inhibitor Partial Response in Gastroesophageal Reflux Disease in Systemic Sclerosis",[55],"2018-05","2018-06","2013-05",250,[22,1269,1270],"Gastroesophageal Reflux","Proton Pubm Inhibitor",[1254],{"trials":1273,"activeCount":66},[],{"trials":1275,"activeCount":66},[],{"trials":1277,"activeCount":66},[],{"trials":1279,"activeCount":66},[],{"intervention":486,"totalTrials":23,"cells":1281},{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1288,"PHASE4":1290,"NA":1296},{"trials":1283,"activeCount":66},[],{"trials":1285,"activeCount":66},[],{"trials":1287,"activeCount":66},[],{"trials":1289,"activeCount":66},[],{"trials":1291,"activeCount":66},[1292],{"nctId":477,"briefTitle":478,"status":244,"phases":1293,"primaryCompletion":480,"completion":480,"start":481,"enrollment":482,"conditions":1294,"interventions":1295},[58],[484],[486,464],{"trials":1297,"activeCount":66},[1298,1309],{"nctId":1299,"briefTitle":1300,"status":244,"phases":1301,"completion":1302,"start":1303,"enrollment":1304,"conditions":1305,"interventions":1307},"NCT00122785","Single Injection of Dexamethasone for Acute Bronchiolitis in Young Children",[59],"2004-09","2002-04",170,[1306],"Bronchiolitis, Viral",[1308],"dexamethasone",{"nctId":1310,"briefTitle":1311,"status":244,"phases":1312,"primaryCompletion":1313,"completion":1313,"start":1314,"enrollment":1315,"conditions":1316,"interventions":1318},"NCT03685032","Effects of Intraoperative Dexamethasone and Ondansetron on Postoperative Nausea and Vomiting in Microvascular Decompression Surgery",[59],"2016-02-16","2014-08-07",54,[1317,19],"Microvascular Decompression Surgery",[486,1319,1320],"Ondansetron","0.9% Sodium Chloride",{"intervention":1322,"totalTrials":538,"cells":1323},"transdermal fentanyl patch",{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1328,"PHASE3":1330,"PHASE4":1332,"NA":1344},{"trials":1325,"activeCount":66},[],{"trials":1327,"activeCount":66},[],{"trials":1329,"activeCount":66},[],{"trials":1331,"activeCount":66},[],{"trials":1333,"activeCount":66},[1334],{"nctId":1335,"briefTitle":1336,"status":244,"phases":1337,"primaryCompletion":1338,"completion":1339,"start":1340,"enrollment":1341,"conditions":1342,"interventions":1343},"NCT01348984","Study of Transdermal Fentanyl Patch to Treat Postoperative Pain in Total Knee Arthroplasty",[58],"2010-10","2010-12","2010-04",40,[29],[1322],{"trials":1345,"activeCount":66},[1346],{"nctId":1347,"briefTitle":1348,"status":244,"phases":1349,"primaryCompletion":1350,"completion":455,"start":1351,"enrollment":199,"conditions":1352,"interventions":1354},"NCT01726530","Transdermal Fentanyl Patch for Postoperative Analgesia After Abdominal Surgery: a Randomized Placebo-controlled Trial",[59],"2011-10","2011-06",[1353],"Postoperative Pain Relief",[1322],{"intervention":1356,"totalTrials":538,"cells":1357},"Normal saline",{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1364,"PHASE4":1366,"NA":1368},{"trials":1359,"activeCount":66},[],{"trials":1361,"activeCount":66},[],{"trials":1363,"activeCount":66},[],{"trials":1365,"activeCount":66},[],{"trials":1367,"activeCount":66},[],{"trials":1369,"activeCount":66},[1370,1381],{"nctId":1371,"briefTitle":1372,"status":195,"phases":1373,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":1376,"conditions":1377,"interventions":1379},"NCT06218680","Efficacy of Low Dose Propofol Given at the End of Sevoflurane Anesthesia for Prevention of Emergence Agitation in Pediatric Patient Undergoing MRI Scan",[59],"2025-04-30","2024-01-20",134,[1378],"Emergence Agitation",[1380,1356],"Propofol",{"nctId":1382,"briefTitle":1383,"status":195,"phases":1384,"primaryCompletion":1385,"completion":1386,"start":1387,"enrollment":142,"conditions":1388,"interventions":1390},"NCT05757388","Efficacy of Parecoxib Combined With Paracetamol in Mastectomy",[59],"2023-05-01","2023-05-10","2023-03-28",[1389],"Post Operative Pain",[1391,1356],"Parecoxib + paracetamol",{"intervention":1393,"totalTrials":62,"cells":1394},"ondansetron adding in PCA",{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1399,"PHASE3":1401,"PHASE4":1403,"NA":1405},{"trials":1396,"activeCount":66},[],{"trials":1398,"activeCount":66},[],{"trials":1400,"activeCount":66},[],{"trials":1402,"activeCount":66},[],{"trials":1404,"activeCount":66},[],{"trials":1406,"activeCount":66},[1407],{"nctId":1408,"briefTitle":1409,"status":244,"phases":1410,"start":1411,"enrollment":1412,"conditions":1413,"interventions":1414},"NCT00199329","Antiemetic Effect of the Addition of Ondansetron to the Morphine Solution in Patient-Controlled Analgesia (PCA)",[59],"2005-01",160,[19],[1393],{"intervention":1380,"totalTrials":62,"cells":1416},{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1423,"PHASE4":1425,"NA":1427},{"trials":1418,"activeCount":66},[],{"trials":1420,"activeCount":66},[],{"trials":1422,"activeCount":66},[],{"trials":1424,"activeCount":66},[],{"trials":1426,"activeCount":66},[],{"trials":1428,"activeCount":66},[1429],{"nctId":1371,"briefTitle":1372,"status":195,"phases":1430,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":1376,"conditions":1431,"interventions":1432},[59],[1378],[1380,1356],{"intervention":1434,"totalTrials":62,"cells":1435},"Quetiapine",{"EARLY_PHASE1":1436,"PHASE1":1438,"PHASE2":1440,"PHASE3":1442,"PHASE4":1444,"NA":1446},{"trials":1437,"activeCount":66},[],{"trials":1439,"activeCount":66},[],{"trials":1441,"activeCount":66},[],{"trials":1443,"activeCount":66},[],{"trials":1445,"activeCount":66},[],{"trials":1447,"activeCount":66},[1448],{"nctId":1449,"briefTitle":1450,"status":244,"phases":1451,"completion":558,"start":1452,"enrollment":1453,"conditions":1454,"interventions":1456},"NCT00328822","Quetiapine for Primary Insomnia Patients : A Randomized Controlled Trial",[59],"2006-12",16,[1455],"Primary Insomnia",[1434],{"intervention":1458,"totalTrials":62,"cells":1459},"cloxacillin and amikacin",{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1468,"NA":1470},{"trials":1461,"activeCount":66},[],{"trials":1463,"activeCount":66},[],{"trials":1465,"activeCount":66},[],{"trials":1467,"activeCount":66},[],{"trials":1469,"activeCount":66},[],{"trials":1471,"activeCount":66},[1472],{"nctId":1473,"briefTitle":1474,"status":244,"phases":1475,"completion":1476,"start":1303,"enrollment":527,"conditions":1477,"interventions":1481},"NCT00129688","Once-Daily Amikacin Plus Cloxacillin in Febrile Neutropenic Children",[59],"2004-06",[1478,1479,1480],"Neutropenia","Cancer","Fever",[1458],{"intervention":1391,"totalTrials":62,"cells":1483},{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1485,"activeCount":66},[],{"trials":1487,"activeCount":66},[],{"trials":1489,"activeCount":66},[],{"trials":1491,"activeCount":66},[],{"trials":1493,"activeCount":66},[],{"trials":1495,"activeCount":66},[1496],{"nctId":1382,"briefTitle":1383,"status":195,"phases":1497,"primaryCompletion":1385,"completion":1386,"start":1387,"enrollment":142,"conditions":1498,"interventions":1499},[59],[1389],[1391,1356],{"intervention":1501,"totalTrials":62,"cells":1502},"Sevoflurane",{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1507,"PHASE3":1509,"PHASE4":1511,"NA":1513},{"trials":1504,"activeCount":66},[],{"trials":1506,"activeCount":66},[],{"trials":1508,"activeCount":66},[],{"trials":1510,"activeCount":66},[],{"trials":1512,"activeCount":66},[],{"trials":1514,"activeCount":66},[1515],{"nctId":1516,"briefTitle":1517,"status":244,"phases":1518,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":318,"conditions":1521,"interventions":1522},"NCT03510013","1-1-8 Wash-in for Sevoflurane Low Flow Anesthesia",[59],"2018-05-31","2018-04-01",[25],[1501],{"intervention":1524,"totalTrials":62,"cells":1525},"spinal morphine",{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1530,"PHASE3":1532,"PHASE4":1534,"NA":1536},{"trials":1527,"activeCount":66},[],{"trials":1529,"activeCount":66},[],{"trials":1531,"activeCount":66},[],{"trials":1533,"activeCount":66},[],{"trials":1535,"activeCount":66},[],{"trials":1537,"activeCount":66},[1538],{"nctId":1539,"briefTitle":1540,"status":195,"phases":1541,"completion":1542,"start":1411,"enrollment":369,"conditions":1543,"interventions":1544},"NCT00199316","Postoperative Pain Control After Kidney Surgery : a Comparison of Intrathecal Morphine Plus PCA and PCA Only",[59],"2005-11",[29],[1524],{"intervention":1546,"totalTrials":62,"cells":1547},"Genotype guided",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1558},{"trials":1549,"activeCount":66},[],{"trials":1551,"activeCount":66},[],{"trials":1553,"activeCount":66},[],{"trials":1555,"activeCount":66},[],{"trials":1557,"activeCount":66},[],{"trials":1559,"activeCount":66},[1560],{"nctId":1561,"briefTitle":1562,"status":195,"phases":1563,"primaryCompletion":1564,"completion":1565,"start":1566,"enrollment":740,"conditions":1567,"interventions":1568},"NCT03173820","Clinical Trial in Assigning of Tacrolimus Dosage Regimen According to CYP3A5 Genotype in Kidney Transplant Recipients",[59],"2017-12-31","2018-06-30","2015-04-30",[661],[1546,1569],"Conventional",{"intervention":1569,"totalTrials":62,"cells":1571},{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1578,"PHASE4":1580,"NA":1582},{"trials":1573,"activeCount":66},[],{"trials":1575,"activeCount":66},[],{"trials":1577,"activeCount":66},[],{"trials":1579,"activeCount":66},[],{"trials":1581,"activeCount":66},[],{"trials":1583,"activeCount":66},[1584],{"nctId":1561,"briefTitle":1562,"status":195,"phases":1585,"primaryCompletion":1564,"completion":1565,"start":1566,"enrollment":740,"conditions":1586,"interventions":1587},[59],[661],[1546,1569],{"intervention":1589,"totalTrials":62,"cells":1590},"clozapine+haloperidol",{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1597,"PHASE4":1599,"NA":1601},{"trials":1592,"activeCount":66},[],{"trials":1594,"activeCount":66},[],{"trials":1596,"activeCount":66},[],{"trials":1598,"activeCount":66},[],{"trials":1600,"activeCount":66},[],{"trials":1602,"activeCount":66},[1603],{"nctId":1604,"briefTitle":1605,"status":244,"phases":1606,"primaryCompletion":526,"completion":1607,"start":1608,"enrollment":456,"conditions":1609,"interventions":1611},"NCT00753051","Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)",[59],"2012-05","2008-06",[1610],"Schizophrenia",[1589,1612],"clozapine,electroconvulsive therapy",{"intervention":1612,"totalTrials":62,"cells":1614},{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1616,"activeCount":66},[],{"trials":1618,"activeCount":66},[],{"trials":1620,"activeCount":66},[],{"trials":1622,"activeCount":66},[],{"trials":1624,"activeCount":66},[],{"trials":1626,"activeCount":66},[1627],{"nctId":1604,"briefTitle":1605,"status":244,"phases":1628,"primaryCompletion":526,"completion":1607,"start":1608,"enrollment":456,"conditions":1629,"interventions":1630},[59],[1610],[1589,1612],{"intervention":1632,"totalTrials":62,"cells":1633},"Esmolol",{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1638,"PHASE3":1640,"PHASE4":1642,"NA":1644},{"trials":1635,"activeCount":66},[],{"trials":1637,"activeCount":66},[],{"trials":1639,"activeCount":66},[],{"trials":1641,"activeCount":66},[],{"trials":1643,"activeCount":66},[],{"trials":1645,"activeCount":66},[1646],{"nctId":1647,"briefTitle":1648,"status":244,"phases":1649,"primaryCompletion":1650,"completion":1651,"start":1652,"enrollment":1653,"conditions":1654,"interventions":1656},"NCT06268275","Comparison of Effects of Scalp Block and Intravenous Esmolol on Hemodynamic Response Following the Skull Pins Application for Elective Supratentorial Craniotomy",[59],"2024-02-01","2024-02-13","2022-09-19",90,[1655],"Hemodynamic Instability",[1632],{"intervention":1658,"totalTrials":62,"cells":1659},"10% lidocaine sprayed",{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1666,"PHASE4":1668,"NA":1670},{"trials":1661,"activeCount":66},[],{"trials":1663,"activeCount":66},[],{"trials":1665,"activeCount":66},[],{"trials":1667,"activeCount":66},[],{"trials":1669,"activeCount":66},[],{"trials":1671,"activeCount":66},[1672],{"nctId":1673,"briefTitle":1674,"status":244,"phases":1675,"primaryCompletion":1035,"completion":1035,"start":1061,"enrollment":1676,"conditions":1677,"interventions":1679},"NCT04090112","Comparison of Effectiveness Between the Combination of Lidocaine Sprayed at Laryngeal Inlet and on the Cuff of Endotracheal Tube Versus Intravenous Lidocaine for Reducing Cough During Extubation",[59],164,[1678],"Reducing Cough During Extubation",[1658,1680],"2% lidocaine intravenous",{"intervention":1680,"totalTrials":62,"cells":1682},{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1687,"PHASE3":1689,"PHASE4":1691,"NA":1693},{"trials":1684,"activeCount":66},[],{"trials":1686,"activeCount":66},[],{"trials":1688,"activeCount":66},[],{"trials":1690,"activeCount":66},[],{"trials":1692,"activeCount":66},[],{"trials":1694,"activeCount":66},[1695],{"nctId":1673,"briefTitle":1674,"status":244,"phases":1696,"primaryCompletion":1035,"completion":1035,"start":1061,"enrollment":1676,"conditions":1697,"interventions":1698},[59],[1678],[1658,1680],{"intervention":1319,"totalTrials":62,"cells":1700},{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1707,"PHASE4":1709,"NA":1711},{"trials":1702,"activeCount":66},[],{"trials":1704,"activeCount":66},[],{"trials":1706,"activeCount":66},[],{"trials":1708,"activeCount":66},[],{"trials":1710,"activeCount":66},[],{"trials":1712,"activeCount":66},[1713],{"nctId":1310,"briefTitle":1311,"status":244,"phases":1714,"primaryCompletion":1313,"completion":1313,"start":1314,"enrollment":1315,"conditions":1715,"interventions":1716},[59],[1317,19],[486,1319,1320],{"intervention":1320,"totalTrials":62,"cells":1718},{"EARLY_PHASE1":1719,"PHASE1":1721,"PHASE2":1723,"PHASE3":1725,"PHASE4":1727,"NA":1729},{"trials":1720,"activeCount":66},[],{"trials":1722,"activeCount":66},[],{"trials":1724,"activeCount":66},[],{"trials":1726,"activeCount":66},[],{"trials":1728,"activeCount":66},[],{"trials":1730,"activeCount":66},[1731],{"nctId":1310,"briefTitle":1311,"status":244,"phases":1732,"primaryCompletion":1313,"completion":1313,"start":1314,"enrollment":1315,"conditions":1733,"interventions":1734},[59],[1317,19],[486,1319,1320],{"intervention":1736,"totalTrials":62,"cells":1737},"The medication following the COPD GOLD guidelines",{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1744,"PHASE4":1746,"NA":1748},{"trials":1739,"activeCount":66},[],{"trials":1741,"activeCount":66},[],{"trials":1743,"activeCount":66},[],{"trials":1745,"activeCount":66},[],{"trials":1747,"activeCount":66},[],{"trials":1749,"activeCount":66},[1750],{"nctId":1751,"briefTitle":1752,"status":195,"phases":1753,"primaryCompletion":883,"completion":1264,"start":1754,"enrollment":199,"conditions":1755,"interventions":1757},"NCT02790047","Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD",[59],"2016-10",[1756],"Chronic Obstructive Pulmonary Disease",[1736],{"intervention":1759,"totalTrials":62,"cells":1760},"pre-operatively followed by 30 mg three times per day after surgery",{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1762,"activeCount":66},[],{"trials":1764,"activeCount":66},[],{"trials":1766,"activeCount":66},[],{"trials":1768,"activeCount":66},[],{"trials":1770,"activeCount":66},[],{"trials":1772,"activeCount":66},[1773],{"nctId":1774,"briefTitle":1775,"status":244,"phases":1776,"completion":1777,"start":1778,"enrollment":318,"conditions":1779,"interventions":1783},"NCT00199303","Efficacy of Pre- and Post-Operative Oral Dextromethorphan",[59],"2003-12","2002-12",[1780,1781,1782],"Efficacy of Dextromethorphan","Morphine Consumption","Pain",[1759]]